Pathogenic role of autoantibodies against inhibitory synapses
Uloženo v:
| Název: | Pathogenic role of autoantibodies against inhibitory synapses |
|---|---|
| Autoři: | Harald Prüss, Knut Kirmse |
| Zdroj: | Brain research 1701, 146-152 (2018). doi:10.1016/j.brainres.2018.09.009 |
| Informace o vydavateli: | Elsevier BV, 2018. |
| Rok vydání: | 2018 |
| Témata: | 0301 basic medicine, Nerve Tissue Proteins, Synaptic Transmission, 03 medical and health sciences, Receptors, Glycine, 0302 clinical medicine, Receptors, GABA, methods [Neuropsychiatry], Animals, Humans, ddc:610, amphiphysin, Autoantibodies, Neurons, 2. Zero hunger, immunology [Synapses], Neurotransmitter Agents, metabolism [Nerve Tissue Proteins], Epilepsy, Movement Disorders, metabolism [Movement Disorders], physiology [Autoantibodies], metabolism [Receptors, Glycine], metabolism [Synapses], immunology [Synaptic Transmission], Neuropsychiatry, Immunity, Humoral, 3. Good health, metabolism [Receptors, GABA], metabolism [Neurons], physiology [Synaptic Transmission], Synapses, metabolism [Autoantibodies], physiology [Immunity, Humoral], metabolism [Epilepsy] |
| Popis: | Diverse neuropsychiatric diseases were recently linked to specific anti-neuronal autoantibodies targeting synaptic proteins. Symptoms can range from epileptic seizures to cognitive impairment to movement disorders, commonly responding to treatment with immunotherapy. Several of these autoantibodies target inhibitory synapses that use GABA or glycine as neurotransmitters. Despite their relatively low abundance, inhibitory neurons are extraordinarily diverse in anatomical, electrophysiological and molecular terms, reflecting the variable clinical phenotypes of affected patients. Indeed, data on the antibody effects in neuronal cultures or animals models suggest that most of these antibodies are directly pathogenic by down-regulating synaptic proteins, activating complement or antagonizing ligand binding. The present review summarizes the current achievements in the field of humoral autoimmunity related to inhibitory networks, state-of-the-art diagnostics and clinical characterization of patients. In many instances, the phenotypic spectrum of patients with GABA receptor, glycine receptor, amphiphysin or GAD65 antibodies mirror the experimental findings, suggesting that ongoing work will markedly contribute to the better understanding of pathophysiology in this exciting patient group and might pave the way for disease-specific immunotherapy. |
| Druh dokumentu: | Article |
| Jazyk: | English |
| ISSN: | 0006-8993 |
| DOI: | 10.1016/j.brainres.2018.09.009 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/30205110 https://www.sciencedirect.com/science/article/abs/pii/S0006899318304669 https://www.ncbi.nlm.nih.gov/pubmed/30205110 https://pubmed.ncbi.nlm.nih.gov/30205110/ |
| Rights: | Elsevier TDM |
| Přístupové číslo: | edsair.doi.dedup.....ab5b62c63e3ca303303b00276bcfcac0 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Diverse neuropsychiatric diseases were recently linked to specific anti-neuronal autoantibodies targeting synaptic proteins. Symptoms can range from epileptic seizures to cognitive impairment to movement disorders, commonly responding to treatment with immunotherapy. Several of these autoantibodies target inhibitory synapses that use GABA or glycine as neurotransmitters. Despite their relatively low abundance, inhibitory neurons are extraordinarily diverse in anatomical, electrophysiological and molecular terms, reflecting the variable clinical phenotypes of affected patients. Indeed, data on the antibody effects in neuronal cultures or animals models suggest that most of these antibodies are directly pathogenic by down-regulating synaptic proteins, activating complement or antagonizing ligand binding. The present review summarizes the current achievements in the field of humoral autoimmunity related to inhibitory networks, state-of-the-art diagnostics and clinical characterization of patients. In many instances, the phenotypic spectrum of patients with GABA receptor, glycine receptor, amphiphysin or GAD65 antibodies mirror the experimental findings, suggesting that ongoing work will markedly contribute to the better understanding of pathophysiology in this exciting patient group and might pave the way for disease-specific immunotherapy. |
|---|---|
| ISSN: | 00068993 |
| DOI: | 10.1016/j.brainres.2018.09.009 |